MEDIA ADVISORY: BIO VentureForum 2002

8:30 - 8:45 a.m.
Welcoming Remarks
Carl B. Feldbaum, president, Biotechnology Industry Organization
8:45 - 10:15 a.m.
The Future of Drug Development: Can We Develop Better Products Faster? What does "best in breed" mean for early stage biotech companies? How does big pharma value contributions to the overall drug development process. A roundtable discussion.

Moderator: Bob Jones, chair, business development, Cooley Godward LLP

Panelists: James N. Woody, M.D., Ph.D, president, Roche Bioscience; Dr. Allen D. Roses, senior vice president of genetic research, GlaxoSmithKline; Russell J. Howard, Ph.D., CEO, Maxygen, Inc.; Brian Cunningham, president & CEO, Rigel Pharmaceuticals, Inc.; Thomas Paterson, chief scientific officer, Entelos, Inc.

11 a.m. - 12:10 p.m.
Commercializing Early-Stage Technology: This panel will focus on the process of helping new companies with early-stage technology get off the ground - from involving the right people and obtaining rights - to the intricacies, tradeoffs and synergies of different financing sources.

Moderator: Mike O'Donnell, partner, Wilson Sonsini Goodrich & Rosati

Panelists: Phyllis Gardner, associate professor of medicine, Stanford University; Jonathan MacQuitty, MA, MBA, Ph.D., director, Abingworth Management Ltd.; Ken Clark, managing partner, Technology Transactions Group, Wilson Sonsini Goodrich & Rosati; Remi Barbier, president, CEO & chairman, Pain Therapeutics, Inc.; Nalini Murdter, Ph.D., senior director, acquisitions, alliances and ventures, Agilent Technologies, Life Sciences & Chemical Analysis

12:15 - 2:00 pm
University-Industry Partnerships in Biotech: Coming of Age
Robert Tjian, Ph.D., Howard Hughes Investigator and professor of biochemistry & molecular biology at UC-Berkeley
2:00 - 3:20 pm
Financing Strategies for Private Biotech Firms: An interactive discussion of trends and strategies for financing in the present capital markets environment. Panelists will address debt transactions, angel investments, venture capital, strategic and alliance financing, and government grants.

Moderator: Barry Brust, partner, corporate, securities and finance practice, Hogan & Hartson LLP

Panelists: Sam Bhaumik, senior vice president and managing director of the Northern California Technology and Life Sciences Division, Comerica Bank; Caroline Carey, vice president, Global Healthcare Group, Lehman Brothers; Joel Marcus, CEO, Alexandria Real Estate Equities, Inc.; Scott Morrison, partner, U.S. Life Sciences Leader, Ernst & Young; Michael Silver, partner, Corporate Securities and Finance Practice, Hogan & Hartson LLP; William Roberts, Partner, Corporate Securities and Finance Practice, Hogan & Hartson LLP; Andy Vestergaard, vice president, Life Sciences, GATX Ventures, Inc.

3:30 - 5:00 pm
Opportunities and Challenges Under a New FDA: While the FDA has been without a permanent commissioner for two years, actions by Congress and the administration will continue to affect biotech companies and their investors. This session will focus on the promises of PDUFA III, recent FDA restructuring, and the intense scrutiny of regulatory relationships between the FDA and companies seeking investment.

Moderator: Jim Snipes, managing partner, San Francisco Office, Covington & Burling

Panelists: Steve Lawton, vice president, regulatory affairs and general counsel, Biotechnology Industry Organization; Richard Kingham, partner, Covington & Burling; William Greene, MD, associate, MPM Capital

BIO represents more than 1,000 biotechnology companies, academic institutions, state biotechnology centers and related organizations in all 50 U.S. states and 33 other nations. BIO members are involved in the research and development of health-care, agricultural, industrial and environmental biotechnology products. For more information, please visit

# # #